Retour

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

Stocks Earnings Releases and Operating Results

U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome

GlobeNewswire Inc. • 07/05/2024 à 12:01:00
X4 Pharmaceuticals, Inc. Common Stock
Address: 61 NORTH BEACON STREET
Postal Code: 02134
City: BOSTON
State: MA
Phone Number: 857-529-8300
Website: https://www.x4pharma.com
Status: Active
Company Info

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

List Date2017-11-16
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001501697
Composite figiBBG001J1CYH8
Share Class figiBBG001TCY1B7
Market Cap155,913,436 USD
SIC Code2836
SIC DescriptionBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Total Employees93
Share Class Shares Outstanding167940000
Weighted Shares Outstanding167937781
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
0.939
0.966
0.97
0.98
0.975
Variance
-2.69%
-0.41%
-1.52%
0.62%
-7.58%
Open
0.965
0.97
0.985
0.974
1.055
Highest
0.987
0.997
1.015
1.015
1.07
Lowest
0.987
0.996
1.015
1.015
1.07
History
PeriodVarhighestlowest
1 week
-11%
1.07
0.987
1 month
-25.83%
1.36
0.987
3 month
-3.2%
0.97
0.865
6 month
18.86%
0.8355
0.5723
1 year
-51.35%
2.17
0.5723
3 year
-87.43%
7.62
0.5723
5 year
-94.71%
18.3
0.5723
10 year
-94%
18
0.5723
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-04 2023-08-10 2023-11-09 UNPUB
Assets 124,405,000 173,399,000 173,293,000 UNPUB
Current Assets 98,222,000 147,649,000 147,872,000 UNPUB
Current Liabilities 19,483,000 22,251,000 25,432,000 UNPUB
Equity 51,676,000 67,535,000 67,594,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 51,676,000 67,535,000 67,594,000 UNPUB
Liabilities 72,729,000 105,864,000 105,699,000 UNPUB
Liabilities And Equity 124,405,000 173,399,000 173,293,000 UNPUB
Noncurrent Assets 26,183,000 25,750,000 25,421,000 UNPUB
Noncurrent Liabilities 53,246,000 83,613,000 80,267,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-04 2023-08-10 2023-11-09 UNPUB
Exchange Gains/Losses 50,000 -6,000 -72,000 UNPUB
Net Cash Flow -28,595,000 -47,900,000 -68,800,000 UNPUB
Net Cash Flow, Continuing -28,645,000 -47,900,000 -68,800,000 UNPUB
Net Cash Flow From Financing Activities -2,124,000 69,338,000 21,205,000 UNPUB
Net Cash Flow From Financing Activities, Continuing -2,124,000 69,338,000 21,205,000 UNPUB
Net Cash Flow From Investing Activities -9,000 -4,884,000 -5,157,000 UNPUB
Net Cash Flow From Investing Activities, Continuing -9,000 -4,884,000 -5,157,000 UNPUB
Net Cash Flow From Operating Activities -26,512,000 -47,900,000 -68,800,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -26,512,000 -47,900,000 -68,800,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-04 2023-08-10 2023-11-09 UNPUB
Comprehensive Income/Loss -24,020,000 -55,712,000 -2,305,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -24,020,000 -55,712,000 -2,305,000 UNPUB
Other Comprehensive Income/Loss 0 0 0 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-04 2023-08-10 2023-11-09 UNPUB
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share 0 0 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -24,020,000 -55,712,000 -2,305,000 UNPUB
Income/Loss From Continuing Operations Before Tax -24,016,000 -55,697,000 -2,279,000 UNPUB
Income Tax Expense/Benefit 4,000 15,000 26,000 UNPUB
Interest Expense, Operating 1,109,000 1,148,000 1,634,000 UNPUB
Net Income/Loss -24,020,000 -55,712,000 -2,305,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -24,020,000 -55,712,000 -2,305,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -24,020,000 -55,712,000 -2,305,000 UNPUB
Operating Expenses 29,304,000 25,805,000 27,214,000 UNPUB
Operating Income/Loss -29,304,000 -25,805,000 -27,214,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 0 0 0 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 UNPUB 2022-11-03 2023-03-21
Assets 99,625,000 UNPUB 113,406,000 155,586,000
Current Assets 70,881,000 UNPUB 85,718,000 128,677,000
Current Liabilities 14,970,000 UNPUB 28,713,000 22,324,000
Equity 49,714,000 UNPUB 61,849,000 74,051,000
Equity Attributable To Noncontrolling Interest 0 UNPUB 0 0
Equity Attributable To Parent 49,714,000 UNPUB 61,849,000 74,051,000
Liabilities 49,911,000 UNPUB 51,557,000 81,535,000
Liabilities And Equity 99,625,000 UNPUB 113,406,000 155,586,000
Noncurrent Assets 28,744,000 UNPUB 27,688,000 26,909,000
Noncurrent Liabilities 0 UNPUB 22,844,000 59,211,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 UNPUB 2022-11-03 2023-03-21
Exchange Gains/Losses -69,000 UNPUB UNPUB -105,000
Net Cash Flow -15,364,000 UNPUB UNPUB 39,920,000
Net Cash Flow, Continuing -15,295,000 UNPUB UNPUB 40,025,000
Net Cash Flow From Financing Activities 4,956,000 UNPUB UNPUB 117,230,000
Net Cash Flow From Financing Activities, Continuing 4,956,000 UNPUB UNPUB 117,230,000
Net Cash Flow From Investing Activities -22,000 UNPUB UNPUB -103,000
Net Cash Flow From Investing Activities, Continuing -22,000 UNPUB UNPUB -103,000
Net Cash Flow From Operating Activities -20,229,000 UNPUB UNPUB -77,102,000
Net Cash Flow From Operating Activities, Continuing -20,229,000 UNPUB UNPUB -77,102,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 UNPUB 2022-11-03 2023-03-21
Comprehensive Income/Loss -21,965,000 UNPUB -21,586,000 -93,867,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 UNPUB 0 0
Comprehensive Income/Loss Attributable To Parent -21,965,000 UNPUB -21,586,000 -93,867,000
Other Comprehensive Income/Loss 0 UNPUB 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 UNPUB 2022-11-03 2023-03-21
Basic Earnings Per Share UNPUB UNPUB 0 -2
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB 0 -2
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -21,965,000 UNPUB -21,586,000 -93,867,000
Income/Loss From Continuing Operations Before Tax -21,942,000 UNPUB -21,599,000 -93,839,000
Income Tax Expense/Benefit 23,000 UNPUB -13,000 28,000
Interest Expense, Operating 913,000 UNPUB 1,018,000 3,993,000
Net Income/Loss -21,965,000 UNPUB -21,586,000 -93,867,000
Net Income/Loss Attributable To Noncontrolling Interest 0 UNPUB 0 0
Net Income/Loss Attributable To Parent -21,965,000 UNPUB -21,586,000 -93,867,000
Net Income/Loss Available To Common Stockholders, Basic -24,224,000 UNPUB -21,873,000 -96,413,000
Operating Expenses 21,268,000 UNPUB 20,154,000 87,569,000
Operating Income/Loss -21,268,000 UNPUB -20,154,000 -87,569,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 UNPUB 287,000 2,546,000
Preferred Stock Dividends And Other Adjustments 0 UNPUB 287,000 2,546,000
Revenues 0 UNPUB 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-03 2021-11-04 2022-03-17
Assets 161,035,000 141,659,000 120,517,000 117,176,000
Current Assets 119,959,000 101,371,000 80,700,000 87,878,000
Current Liabilities 14,672,000 13,120,000 13,232,000 14,023,000
Equity 105,062,000 87,338,000 68,679,000 64,412,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 105,062,000 87,338,000 68,679,000 64,412,000
Liabilities 54,098,000 52,446,000 51,838,000 52,764,000
Liabilities And Equity 161,035,000 141,659,000 120,517,000 117,176,000
Noncurrent Assets 41,076,000 40,288,000 39,817,000 29,298,000
Noncurrent Liabilities 0 0 38,606,000 38,741,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-03 2021-11-04 2022-03-17
Exchange Gains/Losses -143,000 40,000 -100,000 -319,000
Net Cash Flow 35,958,000 -20,167,000 -18,773,000 2,406,000
Net Cash Flow, Continuing 36,101,000 -20,207,000 -18,673,000 2,725,000
Net Cash Flow From Financing Activities 55,041,000 -924,000 -4,442,000 74,245,000
Net Cash Flow From Financing Activities, Continuing 55,041,000 -924,000 -4,442,000 74,245,000
Net Cash Flow From Investing Activities -496,000 -86,000 -20,000 -615,000
Net Cash Flow From Investing Activities, Continuing -496,000 -86,000 -20,000 -615,000
Net Cash Flow From Operating Activities -18,444,000 -19,197,000 -14,211,000 -70,905,000
Net Cash Flow From Operating Activities, Continuing -18,444,000 -19,197,000 -14,211,000 -70,905,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-03 2021-11-04 2022-03-17
Comprehensive Income/Loss -18,676,000 -19,638,000 -20,175,000 -88,696,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -18,676,000 -19,638,000 -20,175,000 -88,696,000
Other Comprehensive Income/Loss 0 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-03 2021-11-04 2022-03-17
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -18,676,000 -19,638,000 -20,175,000 -88,696,000
Income/Loss From Continuing Operations Before Tax -18,670,000 -19,632,000 -20,173,000 -88,679,000
Income Tax Expense/Benefit 6,000 6,000 2,000 17,000
Interest Expense, Operating 891,000 905,000 920,000 3,642,000
Net Income/Loss -18,676,000 -19,638,000 -20,175,000 -88,696,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -18,676,000 -19,638,000 -20,175,000 -88,696,000
Net Income/Loss Available To Common Stockholders, Basic -26,915,000 -19,638,000 -20,175,000 -102,639,000
Operating Expenses 17,936,000 18,997,000 19,119,000 85,107,000
Operating Income/Loss -17,936,000 -18,997,000 -19,119,000 -85,107,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 13,943,000
Preferred Stock Dividends And Other Adjustments 0 0 0 13,943,000
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-07 2020-08-04 2020-11-05 2021-03-19
Assets 153,717,000 142,534,000 133,126,000 122,871,000
Current Assets 121,950,000 109,887,000 93,913,000 83,307,000
Current Liabilities 7,950,000 10,781,000 13,179,000 11,948,000
Equity 118,791,000 104,884,000 89,708,000 72,799,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 118,791,000 104,884,000 89,708,000 72,799,000
Liabilities 34,926,000 37,650,000 43,418,000 50,072,000
Liabilities And Equity 153,717,000 142,534,000 133,126,000 122,871,000
Noncurrent Assets 31,767,000 32,647,000 39,213,000 39,564,000
Noncurrent Liabilities 0 0 30,239,000 38,124,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-07 2020-08-04 2020-11-05 2021-03-19
Exchange Gains/Losses -34,000 94,000 180,000 402,000
Net Cash Flow -11,132,000 -11,309,000 -14,928,000 -47,384,000
Net Cash Flow, Continuing -11,098,000 -11,403,000 -15,108,000 -47,786,000
Net Cash Flow From Financing Activities 4,984,000 65,000 -284,000 12,394,000
Net Cash Flow From Financing Activities, Continuing 4,984,000 65,000 -284,000 12,394,000
Net Cash Flow From Investing Activities -555,000 -9,000 -496,000 -1,362,000
Net Cash Flow From Investing Activities, Continuing -555,000 -9,000 -496,000 -1,362,000
Net Cash Flow From Operating Activities -15,527,000 -11,459,000 -14,328,000 -58,818,000
Net Cash Flow From Operating Activities, Continuing -15,527,000 -11,459,000 -14,328,000 -58,818,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-07 2020-08-04 2020-11-05 2021-03-19
Comprehensive Income/Loss -11,138,000 -15,144,000 -17,449,000 -62,131,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -11,138,000 -15,144,000 -17,449,000 -62,131,000
Other Comprehensive Income/Loss 0 0 -17,449,000 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-07 2020-08-04 2020-11-05 2021-03-19
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses 13,990,000 15,144,000 17,449,000 64,983,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 13,990,000 15,144,000 17,449,000 64,983,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -11,138,000 -15,144,000 -17,449,000 -62,131,000
Income/Loss From Continuing Operations Before Tax -10,990,000 -15,144,000 -17,449,000 -61,983,000
Income Tax Expense/Benefit 148,000 0 0 148,000
Interest Expense, Operating 584,000 687,000 697,000 2,688,000
Net Income/Loss -11,138,000 -15,144,000 -17,449,000 -62,131,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -11,138,000 -15,144,000 -17,449,000 -62,131,000
Net Income/Loss Available To Common Stockholders, Basic -11,138,000 -15,144,000 -17,449,000 -62,131,000
Operating Expenses 13,581,000 14,658,000 16,980,000 62,874,000
Operating Income/Loss -10,581,000 -14,658,000 -16,980,000 -59,874,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 3,000,000 0 0 3,000,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-15 2019-08-07 2019-11-07 2020-03-12
Assets 62,549,000 133,507,000 109,537,000 160,698,000
Current Assets 26,223,000 96,649,000 79,215,000 129,278,000
Current Liabilities 16,450,000 13,204,000 8,279,000 9,447,000
Equity 29,440,000 96,167,000 79,107,000 129,220,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 29,440,000 96,167,000 79,107,000 129,220,000
Liabilities 33,108,000 37,339,000 30,430,000 31,478,000
Liabilities And Equity 62,549,000 133,507,000 109,537,000 160,698,000
Noncurrent Assets 36,326,000 36,858,000 30,322,000 31,420,000
Noncurrent Liabilities 0 0 22,151,000 22,031,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-15 2019-08-07 2019-11-07 2020-03-12
Exchange Gains/Losses -21,000 19,000 -264,000 -250,000
Net Cash Flow 14,748,000 72,395,000 -18,635,000 119,588,000
Net Cash Flow, Continuing 14,769,000 72,376,000 -18,371,000 119,838,000
Net Cash Flow From Financing Activities 113,000 86,678,000 -6,414,000 140,661,000
Net Cash Flow From Financing Activities, Continuing 113,000 86,678,000 -6,414,000 140,661,000
Net Cash Flow From Investing Activities 26,406,000 -10,000 815,000 27,232,000
Net Cash Flow From Investing Activities, Continuing 26,406,000 -10,000 815,000 27,232,000
Net Cash Flow From Operating Activities -11,750,000 -14,292,000 -12,772,000 -48,055,000
Net Cash Flow From Operating Activities, Continuing -11,750,000 -14,292,000 -12,772,000 -48,055,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-15 2019-08-07 2019-11-07 2020-03-12
Comprehensive Income/Loss -10,873,000 -13,383,000 -17,791,000 -52,926,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -10,850,000 -13,448,000 -17,791,000 -52,926,000
Other Comprehensive Income/Loss 0 0 -17,791,000 -119,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-15 2019-08-07 2019-11-07 2020-03-12
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -10,873,000 -13,383,000 -17,714,000 -52,807,000
Income/Loss From Continuing Operations Before Tax -10,873,000 -13,383,000 -17,714,000 -52,807,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating 399,000 512,000 688,000 2,147,000
Net Income/Loss 10,873,000 -13,383,000 -17,714,000 -52,807,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -10,873,000 -13,383,000 -17,714,000 -52,807,000
Net Income/Loss Available To Common Stockholders, Basic -11,465,000 -13,383,000 -17,714,000 -53,399,000
Operating Expenses 10,438,000 13,414,000 16,976,000 51,703,000
Operating Income/Loss -10,438,000 -13,414,000 -16,976,000 -51,703,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 592,000
Preferred Stock Dividends And Other Adjustments 0 0 0 592,000
Revenues 0 0 0 0
Calendar
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:XFOR240517P00004000 OPASPS Put American 100 4 BATO 2024-05-17
O:XFOR240517P00003000 OPASPS Put American 100 3 BATO 2024-05-17
O:XFOR240517P00002000 OPASPS Put American 100 2 BATO 2024-05-17
O:XFOR240517P00001500 OPASPS Put American 100 1.5 BATO 2024-05-17
O:XFOR240517P00001000 OPASPS Put American 100 1 BATO 2024-05-17
O:XFOR240517P00000500 OPASPS Put American 100 0.5 BATO 2024-05-17
O:XFOR240517C00004000 OCASPS Call American 100 4 BATO 2024-05-17
O:XFOR240517C00003000 OCASPS Call American 100 3 BATO 2024-05-17
O:XFOR240517C00002000 OCASPS Call American 100 2 BATO 2024-05-17
O:XFOR240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:XFOR240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:XFOR240517C00001500 OCASPS Call American 100 1.5 BATO 2024-05-17
O:XFOR240517C00001000 OCASPS Call American 100 1 BATO 2024-05-17
O:XFOR240517C00000500 OCASPS Call American 100 0.5 BATO 2024-05-17
O:XFOR240419P00001500 OPASPS Put American 100 1.5 BATO 2024-04-19
O:XFOR240419P00000500 OPASPS Put American 100 0.5 BATO 2024-04-19
O:XFOR240419C00001500 OCASPS Call American 100 1.5 BATO 2024-04-19
O:XFOR240419C00000500 OCASPS Call American 100 0.5 BATO 2024-04-19
O:XFOR240419P00004000 OPASPS Put American 100 4 BATO 2024-04-19
O:XFOR240419P00003000 OPASPS Put American 100 3 BATO 2024-04-19
O:XFOR240419P00002000 OPASPS Put American 100 2 BATO 2024-04-19
O:XFOR240419P00001000 OPASPS Put American 100 1 BATO 2024-04-19
O:XFOR240419C00004000 OCASPS Call American 100 4 BATO 2024-04-19
O:XFOR240419C00003000 OCASPS Call American 100 3 BATO 2024-04-19
O:XFOR240419C00002000 OCASPS Call American 100 2 BATO 2024-04-19
O:XFOR240419C00001000 OCASPS Call American 100 1 BATO 2024-04-19
O:XFOR240315P00004000 OPASPS Put American 100 4 BATO 2024-03-15
O:XFOR240315P00003000 OPASPS Put American 100 3 BATO 2024-03-15
O:XFOR240315P00002000 OPASPS Put American 100 2 BATO 2024-03-15
O:XFOR240315P00001000 OPASPS Put American 100 1 BATO 2024-03-15
O:XFOR240315C00004000 OCASPS Call American 100 4 BATO 2024-03-15
O:XFOR240315C00003000 OCASPS Call American 100 3 BATO 2024-03-15
O:XFOR240315C00002000 OCASPS Call American 100 2 BATO 2024-03-15
O:XFOR240315C00001000 OCASPS Call American 100 1 BATO 2024-03-15
O:XFOR240315P00000500 OPASPS Put American 100 0.5 BATO 2024-03-15
O:XFOR240315C00000500 OCASPS Call American 100 0.5 BATO 2024-03-15
O:XFOR240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:XFOR240216P00001500 OPASPS Put American 100 1.5 BATO 2024-02-16
O:XFOR240216P00000500 OPASPS Put American 100 0.5 BATO 2024-02-16
O:XFOR240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:XFOR240216C00001500 OCASPS Call American 100 1.5 BATO 2024-02-16
O:XFOR240216C00000500 OCASPS Call American 100 0.5 BATO 2024-02-16
O:XFOR240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:XFOR240216P00004000 OPASPS Put American 100 4 BATO 2024-02-16
O:XFOR240216P00003000 OPASPS Put American 100 3 BATO 2024-02-16
O:XFOR240216P00002000 OPASPS Put American 100 2 BATO 2024-02-16
O:XFOR240216P00001000 OPASPS Put American 100 1 BATO 2024-02-16
O:XFOR240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:XFOR240216C00004000 OCASPS Call American 100 4 BATO 2024-02-16
O:XFOR240216C00003000 OCASPS Call American 100 3 BATO 2024-02-16
O:XFOR240216C00002000 OCASPS Call American 100 2 BATO 2024-02-16
O:XFOR240216C00001000 OCASPS Call American 100 1 BATO 2024-02-16
O:XFOR240119P00004000 OPASPS Put American 100 4 BATO 2024-01-19
O:XFOR240119P00003000 OPASPS Put American 100 3 BATO 2024-01-19
O:XFOR240119P00002000 OPASPS Put American 100 2 BATO 2024-01-19
O:XFOR240119P00001000 OPASPS Put American 100 1 BATO 2024-01-19
O:XFOR240119C00004000 OCASPS Call American 100 4 BATO 2024-01-19
O:XFOR240119C00003000 OCASPS Call American 100 3 BATO 2024-01-19
O:XFOR240119C00002000 OCASPS Call American 100 2 BATO 2024-01-19
O:XFOR240119C00001000 OCASPS Call American 100 1 BATO 2024-01-19
O:XFOR231215P00004000 OPASPS Put American 100 4 BATO 2023-12-15
O:XFOR231215P00003000 OPASPS Put American 100 3 BATO 2023-12-15
O:XFOR231215P00002000 OPASPS Put American 100 2 BATO 2023-12-15
O:XFOR231215P00001000 OPASPS Put American 100 1 BATO 2023-12-15
O:XFOR231215C00004000 OCASPS Call American 100 4 BATO 2023-12-15
O:XFOR231215C00003000 OCASPS Call American 100 3 BATO 2023-12-15
O:XFOR231215C00002000 OCASPS Call American 100 2 BATO 2023-12-15
O:XFOR231215C00001000 OCASPS Call American 100 1 BATO 2023-12-15
O:XFOR231117P00006000 OPASPS Put American 100 6 BATO 2023-11-17
O:XFOR231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:XFOR231117P00004000 OPASPS Put American 100 4 BATO 2023-11-17
O:XFOR231117P00003000 OPASPS Put American 100 3 BATO 2023-11-17
O:XFOR231117P00002000 OPASPS Put American 100 2 BATO 2023-11-17
O:XFOR231117P00001000 OPASPS Put American 100 1 BATO 2023-11-17
O:XFOR231117C00006000 OCASPS Call American 100 6 BATO 2023-11-17
O:XFOR231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:XFOR231117C00004000 OCASPS Call American 100 4 BATO 2023-11-17
O:XFOR231117C00003000 OCASPS Call American 100 3 BATO 2023-11-17
O:XFOR231117C00002000 OCASPS Call American 100 2 BATO 2023-11-17
O:XFOR231117C00001000 OCASPS Call American 100 1 BATO 2023-11-17
O:XFOR231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:XFOR231117P00001500 OPASPS Put American 100 1.5 BATO 2023-11-17
O:XFOR231117P00000500 OPASPS Put American 100 0.5 BATO 2023-11-17
O:XFOR231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:XFOR231117C00001500 OCASPS Call American 100 1.5 BATO 2023-11-17
O:XFOR231117C00000500 OCASPS Call American 100 0.5 BATO 2023-11-17
O:XFOR231020C00004000 OCASPS Call American 100 4 BATO 2023-10-20
O:XFOR231020C00003000 OCASPS Call American 100 3 BATO 2023-10-20
O:XFOR231020C00002000 OCASPS Call American 100 2 BATO 2023-10-20
O:XFOR231020C00001000 OCASPS Call American 100 1 BATO 2023-10-20
O:XFOR231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:XFOR231020P00001500 OPASPS Put American 100 1.5 BATO 2023-10-20
O:XFOR231020P00000500 OPASPS Put American 100 0.5 BATO 2023-10-20
O:XFOR231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:XFOR231020C00001500 OCASPS Call American 100 1.5 BATO 2023-10-20
O:XFOR231020C00000500 OCASPS Call American 100 0.5 BATO 2023-10-20
O:XFOR231020P00004000 OPASPS Put American 100 4 BATO 2023-10-20
O:XFOR231020P00003000 OPASPS Put American 100 3 BATO 2023-10-20
O:XFOR231020P00002000 OPASPS Put American 100 2 BATO 2023-10-20
O:XFOR231020P00001000 OPASPS Put American 100 1 BATO 2023-10-20
O:XFOR230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:XFOR230915P00004000 OPASPS Put American 100 4 BATO 2023-09-15
O:XFOR230915P00003000 OPASPS Put American 100 3 BATO 2023-09-15
O:XFOR230915P00002000 OPASPS Put American 100 2 BATO 2023-09-15
O:XFOR230915P00001000 OPASPS Put American 100 1 BATO 2023-09-15
O:XFOR230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:XFOR230915C00004000 OCASPS Call American 100 4 BATO 2023-09-15
O:XFOR230915C00003000 OCASPS Call American 100 3 BATO 2023-09-15
O:XFOR230915C00002000 OCASPS Call American 100 2 BATO 2023-09-15
O:XFOR230915C00001000 OCASPS Call American 100 1 BATO 2023-09-15
O:XFOR230818P00006000 OPASPS Put American 100 6 BATO 2023-08-18
O:XFOR230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:XFOR230818P00004000 OPASPS Put American 100 4 BATO 2023-08-18
O:XFOR230818P00003000 OPASPS Put American 100 3 BATO 2023-08-18
O:XFOR230818P00002000 OPASPS Put American 100 2 BATO 2023-08-18
O:XFOR230818P00001000 OPASPS Put American 100 1 BATO 2023-08-18
O:XFOR230818C00006000 OCASPS Call American 100 6 BATO 2023-08-18
O:XFOR230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:XFOR230818C00004000 OCASPS Call American 100 4 BATO 2023-08-18
O:XFOR230818C00003000 OCASPS Call American 100 3 BATO 2023-08-18
O:XFOR230818C00002000 OCASPS Call American 100 2 BATO 2023-08-18
O:XFOR230818C00001000 OCASPS Call American 100 1 BATO 2023-08-18
News Stream
Stocks Financing Agreements
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
$125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor)
GlobeNewswire Inc. • 1w ago
Stocks Earnings Releases and Operating Results
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome
GlobeNewswire Inc. • 1w ago
Stocks Major shareholder announcements
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on April 30, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 605,349 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
GlobeNewswire Inc. • 2w ago
News Regulatory information
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndrome
GlobeNewswire Inc. • 2w ago
Stocks Changes in company's own shares
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on April 1, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 1,164,470 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming Needham 23rd Annual Healthcare Conference being held virtually from April 8-11, 2024, and the Piper Sandler Spring Biopharma Symposium being held in Boston from April 16-17, 2024.
GlobeNewswire Inc. • 1mo ago
Stocks Earnings Releases and Operating Results
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
Launch preparations underway in anticipation of possible U.S. approval of mavorixafor for WHIM syndrome; U.S. PDUFA target action date set for April 30, 2024
GlobeNewswire Inc. • 1mo ago
Stocks Stock Market News
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on February 29, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 1,524,112 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
GlobeNewswire Inc. • 2mo ago
Stocks Stock Market News
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 575,942 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
GlobeNewswire Inc. • 3mo ago
News Clinical Study
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
Initial data continue to support advancement of mavorixafor into pivotal, global Phase 3 trial in certain chronic neutropenic disorders; company on track to initiate in 1H 2024
GlobeNewswire Inc. • 5mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT